Dalriada’s Turn-Key Drug Discovery model is specifically designed to provide ultimate support for semi-virtual lean biotechs developing small molecule therapies.
We uniquely integrate internal R&D, end-to-end program management, business and IP support to unlock the most rapid and agile program execution and ultimately the fastest route to the clinic.
​
We focus on value building for each client and partner and conduct all programs with an R&D-to-milestone approach. Drawing experience from Pharma, Biotech, VC, and Academia, Dalriada’s team equally understands both the science and business needs, which allows for a seamless collaboration with the biotech client or a fully autonomous project execution.